NASDAQ:CEMI Chembio Diagnostics - CEMI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Chembio Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.39 +0.01 (+2.63%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.38▼$0.4050-Day Range$0.33▼$0.4552-Week Range$0.19▼$1.24Volume529,058 shsAverage Volume550,037 shsMarket Capitalization$14.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Chembio Diagnostics (NASDAQ:CEMI) StockChembio Diagnostics, Inc. engages in the developing, manufacturing, marketing, and licensing of rapid medical tests. It offers rapid point-of-care tests for infectious, tropical and fever, and respiratory diseases, handheld analyzers, and veterinary products. The firm distributes its products to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. The company was founded in 1985 and is headquartered in Hauppauge, NY.Read More Receive CEMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CEMI Stock News HeadlinesMarch 22, 2023 | americanbankingnews.comChembio Diagnostics (NASDAQ:CEMI) Now Covered by Analysts at StockNews.comMarch 21, 2023 | finance.yahoo.comChembio Stockholders Reminded to Tender Shares Before 6:00 PM New York City Time, on March 28, 2023March 25, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 15, 2023 | finance.yahoo.comBiosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.March 15, 2023 | finance.yahoo.comChembio Announces Letter to Stockholders Regarding Tender OfferFebruary 24, 2023 | finance.yahoo.comChembio Announces the Receipt of CLIA Waiver for its DPP HIV-Syphilis SystemFebruary 8, 2023 | benzinga.comMoore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law FirmFebruary 2, 2023 | wsj.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Chembio Diagnostics, Inc. BuyoutMarch 25, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.February 1, 2023 | finance.yahoo.comFrench Rapid Testing Company Scoops Up Chembio Diagnostics For $17MJanuary 31, 2023 | finance.yahoo.comBiosynex and Chembio Diagnostics Announce Definitive Acquisition AgreementJanuary 21, 2023 | seekingalpha.comCEMI Chembio Diagnostics, Inc.January 7, 2023 | forbes.comChembio DiagnosticsNovember 28, 2022 | finance.yahoo.comChembio Announces FDA CLIA Waiver Submission for DPP HIV-Syphilis SystemNovember 6, 2022 | seekingalpha.comChembio Diagnostics, Inc. (CEMI) Q3 2022 Earnings Call TranscriptNovember 3, 2022 | finance.yahoo.comChembio Diagnostics Reports Third Quarter 2022 Financial ResultsOctober 20, 2022 | finance.yahoo.comChembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022September 6, 2022 | finance.yahoo.comChembio Diagnostics Awarded $3.2 Million Contract from the CDC for Development and Clinical Validation of Dual-Path Platform Syphilis Screen & Confirm AssaySeptember 3, 2022 | finance.yahoo.comIs Monkeypox Outbreak Cooling? Health Officials Says Virus Transmission Has SlowedAugust 16, 2022 | finance.yahoo.comRapid Test For Monkeypox? NY-Based Chembio Diagnostics Thinks They Can Pull It OffAugust 16, 2022 | finance.yahoo.comChembio Diagnostics Evaluates Monkeypox Rapid Point-of-Care Test DevelopmentAugust 4, 2022 | finance.yahoo.comChembio Diagnostics Reports Second Quarter 2022 Financial ResultsJuly 21, 2022 | finance.yahoo.comChembio Diagnostics to Report Second Quarter 2022 Financial Results on August 4, 2022June 15, 2022 | baystreet.caChembio Expands DistributionJune 15, 2022 | finance.yahoo.comChembio Diagnostics Announces Expansion of Direct-to-Consumer Commercial ChannelMay 17, 2022 | seekingalpha.comChembio's inks contract for HIV test to be made by Reszon Diagnostics at Malaysia facilityMay 17, 2022 | finance.yahoo.comChembio Diagnostics Announces Agreement for Reszon Diagnostics International to Manufacture Chembio’s HIV 1/2 STAT-PAK Assay at Chembio Diagnostics Malaysia FacilitySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CEMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chembio Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CEMI Company Calendar Last Earnings11/04/2021Today3/25/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CEMI CUSIPN/A CIK1092662 Webwww.chembio.com Phone(631) 924-1135Fax631-924-2065Employees337Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,900,000.00 Net Margins-60.93% Pretax Margin-60.91% Return on Equity-129.14% Return on Assets-50.01% Debt Debt-to-Equity Ratio0.01 Current Ratio1.22 Quick Ratio1.00 Sales & Book Value Annual Sales$47.82 million Price / Sales0.30 Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book0.34Miscellaneous Outstanding Shares36,710,000Free Float35,497,000Market Cap$14.32 million OptionableNot Optionable Beta1.83 Key ExecutivesRichard L. EberlyPresident, Chief Executive Officer & DirectorPaul J. AngelicoChief Operations Officer & Executive VPLawrence J. SteenvoordenChief Financial Officer, Secretary & Executive VPJavan EsfandiariExecutive VP, Chief Science & Technology OfficerPaul LambotteVice President-Research & DevelopmentKey CompetitorsTempest TherapeuticsNASDAQ:TPSTIndaptus TherapeuticsNASDAQ:INDPRedHill BiopharmaNASDAQ:RDHLHumanigenNASDAQ:HGENCellectar BiosciencesNASDAQ:CLRBView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 22,800 shares on 2/13/2023Ownership: 0.372%Simplex Trading LLCBought 8,000 shares on 2/2/2023Ownership: 0.000%View All Institutional Transactions CEMI Stock - Frequently Asked Questions How have CEMI shares performed in 2023? Chembio Diagnostics' stock was trading at $0.2197 at the start of the year. Since then, CEMI shares have increased by 77.5% and is now trading at $0.39. View the best growth stocks for 2023 here. When is Chembio Diagnostics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our CEMI earnings forecast. How were Chembio Diagnostics' earnings last quarter? Chembio Diagnostics, Inc. (NASDAQ:CEMI) announced its quarterly earnings data on Thursday, November, 4th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.05. The company had revenue of $12.06 million for the quarter. Chembio Diagnostics had a negative net margin of 60.93% and a negative trailing twelve-month return on equity of 129.14%. During the same period in the prior year, the company earned ($0.28) earnings per share. What other stocks do shareholders of Chembio Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), NovoCure (NVCR), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Roper Technologies (ROP) and ReWalk Robotics (RWLK). What is Chembio Diagnostics' stock symbol? Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI." Who are Chembio Diagnostics' major shareholders? Chembio Diagnostics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.37%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). View institutional ownership trends. How do I buy shares of Chembio Diagnostics? Shares of CEMI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Chembio Diagnostics' stock price today? One share of CEMI stock can currently be purchased for approximately $0.39. How much money does Chembio Diagnostics make? Chembio Diagnostics (NASDAQ:CEMI) has a market capitalization of $14.32 million and generates $47.82 million in revenue each year. The company earns $-33,900,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. How many employees does Chembio Diagnostics have? The company employs 337 workers across the globe. How can I contact Chembio Diagnostics? Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The official website for the company is www.chembio.com. The company can be reached via phone at (631) 924-1135, via email at investor@chembio.com, or via fax at 631-924-2065. This page (NASDAQ:CEMI) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.